ced °Ë»ö°á°ú
100 °Ç (1/10 ÂÊ)
»ó¼¼Á¶°Ç 
 
ÆÄÀÏÁ¾·ù 
|
GSK±â¾÷¼Ò°³¿Í R&D±¸Á¶,ȯ°æº¯È,CEDD±¸Á¶ ¹× Á÷¸éÇÏ°Ô µÉ µµÀü / Glaxo SmithKline -±â¾÷»ç·Ê ºÐ¼®- `¸ñÂ÷` 1.±â¾÷¼Ò°³ 2-1.Á¦¾à»ê¾÷ÀÇ ÀüÅëÀû R&DÁ¶Á÷ 2-2.ÇÕº´ÀÌÀü GSKÀÇ R&D±¸Á¶ ¹× Ư¡ 3. ȯ°æº¯È ºÐ¼® 4. ±âÁ¸ Á¦¾à¾÷üÀÇ R&D Á¶Á÷±¸Á¶ÀÇ ¹®Á¦Á¡ 5-1 CEDD ±¸Á¶ÀÇ Á¤ÀÇ¿Í µîÀå¹è°æ 5-2 CEDD±¸Á¶ Ư¡°ú, °¢ Ư¡¿¡ µû¸¥ °Á¡°ú ¾àÁ¡ 5-3 CEDDs½Å¼³À» ÇÙ½ÉÀ¸·Î ÇÏ¿© R&D ¡¦ |
|
|
|
|
|
GSK±â¾÷¼Ò°³¿Í R&D±¸Á¶,ȯ°æº¯È,CEDD±¸Á¶ ¹× Á÷¸éÇÏ°Ô µÉ µµÀü / contents 0 1. GSK±â¾÷¼Ò°³ 2. R&D ±¸Á¶ 4. CEDD±¸Á¶ 3. Á¦¾à»ê¾÷ ȯ°æº¯È 5.Á÷¸éÇÏ°ÔµÉ µµÀü 6.°á·Ð (1)Á¦¾à»ê¾÷ Àü¹Ý (2)ÇÕº´ÀÌ¡¦ |
|
|
|
|